Efficacy and Safety of the APGO Algorithm for Automated Insulin Delivery
ConditionDiabetes Mellitus Type 1
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorCharles University, Czech Republic
About this trial
The Medtrum TouchCare Nano system with the APGO algorithm is the only patch pump-based automated insulin delivery system available in the Czech Republic. However, until now, no prospective clinical study has evaluated its efficacy and safety under real-world conditions. The RENEW study is the first to address this topic.
Eligibility criteria
Qualifiers
patients with T1D
type 1 diabetes for ≥1 years
≥ 18 years old
written informed consent prior to starting study related activity
Disqualifiers
severe noncompliance
lactation, pregnancy, intending to become pregnant during study
use of medication with effects on carbohydrate metabolism
Trial design
Treatments tested in this trial
- Device: Insulin pump TouchCare Nano A8 with the APGO system
Treatment groups
200 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov